OrthoPediatrics (NASDAQ:KIDS) Rating Lowered to “Sell” at Wall Street Zen

OrthoPediatrics (NASDAQ:KIDS) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Several other brokerages have also issued reports on KIDS. Canaccord Genuity Group started coverage on shares of OrthoPediatrics in a report on Wednesday, December 10th. They set a “buy” rating and a $24.00 price objective on the stock. Truist Financial set a $18.00 price target on OrthoPediatrics in a report on Friday, October 10th. Lake Street Capital reduced their price target on OrthoPediatrics from $37.00 to $34.00 and set a “buy” rating for the company in a research report on Friday, October 10th. Weiss Ratings restated a “sell (e+)” rating on shares of OrthoPediatrics in a research note on Wednesday, October 8th. Finally, JMP Securities dropped their price objective on OrthoPediatrics from $35.00 to $25.00 and set a “market outperform” rating on the stock in a research report on Friday, October 10th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

OrthoPediatrics Stock Performance

KIDS stock opened at $17.07 on Friday. OrthoPediatrics has a 1-year low of $15.28 and a 1-year high of $27.60. The business has a 50-day moving average price of $17.46 and a 200 day moving average price of $19.43. The company has a market capitalization of $428.12 million, a P/E ratio of -8.75 and a beta of 1.06. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.40 and a quick ratio of 3.52.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Monday, January 9th. The company reported ($0.15) earnings per share (EPS) for the quarter. OrthoPediatrics had a negative return on equity of 6.86% and a negative net margin of 20.06%.The business had revenue of $25.08 million for the quarter. As a group, equities research analysts forecast that OrthoPediatrics will post -0.93 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. boosted its holdings in OrthoPediatrics by 112.3% in the first quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock worth $4,937,000 after acquiring an additional 106,041 shares in the last quarter. Harbor Capital Advisors Inc. raised its position in shares of OrthoPediatrics by 116.5% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 333,959 shares of the company’s stock valued at $7,173,000 after purchasing an additional 179,733 shares during the last quarter. Invesco Ltd. raised its position in shares of OrthoPediatrics by 12.1% in the 1st quarter. Invesco Ltd. now owns 18,349 shares of the company’s stock valued at $452,000 after purchasing an additional 1,986 shares during the last quarter. Triodos Investment Management BV boosted its stake in OrthoPediatrics by 25.0% in the 2nd quarter. Triodos Investment Management BV now owns 112,500 shares of the company’s stock worth $2,415,000 after purchasing an additional 22,500 shares in the last quarter. Finally, American Century Companies Inc. grew its position in OrthoPediatrics by 16.1% during the 1st quarter. American Century Companies Inc. now owns 30,658 shares of the company’s stock worth $755,000 after purchasing an additional 4,248 shares during the last quarter. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.